embecta-sponsored Abstracts Presented at American Diabetes Association’s 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin Reservoir
Embecta presented two abstracts at the ADA's 84th Scientific Sessions, highlighting the potential benefits of a 300-unit insulin reservoir patch pump for adults with type 2 diabetes (T2D). Research indicated that the larger reservoir could reduce the need for frequent patch changes and better accommodate daily insulin needs. One study found that insulin total daily dose (TDD) was influenced by factors such as BMI and medication type. Another analysis showed that a 300u reservoir would meet the needs of 64% of T2D patients for 72-hour wear compared to 38% for a 200u reservoir. Embecta has submitted a 300u insulin delivery system to the FDA for approval.
- Presented data at ADA's 84th Scientific Sessions, enhancing company visibility.
- 300u insulin reservoir patch pump could meet the needs of 64% of T2D patients for 72-hour wear.
- Embecta submitted a 300u insulin delivery system to the FDA for approval, indicating potential future product availability.
- Study showed larger reservoir patch pumps reduce frequency and cost of changing disposable pumps.
- Data showed insulin TDD was lower among African Americans and women, possibly indicating unequal treatment efficacy.
- Only 38% of T2D patients' needs would be met by a 200u insulin reservoir for 72-hour wear, highlighting limitations of smaller reservoirs.
Insights
Embecta's recent presentation at the American Diabetes Association’s Scientific Sessions showcases critical findings about insulin delivery for adults with type 2 diabetes (T2D). The focus is on the efficacy and benefits of a larger, 300-unit insulin reservoir in patch pumps. This innovation aims to reduce the frequency of changing disposable patches, a significant improvement for T2D patients who require multiple daily injections.
From a medical research perspective, the larger reservoir's capacity is particularly beneficial for those with higher insulin needs, likely due to factors like increased BMI or the usage of certain diabetes medications, such as SGLT-2 inhibitors and GLP-1RAs, which the study highlighted. Streamlining insulin delivery can enhance patient adherence to treatment regimens, thereby improving overall health outcomes.
Short-term impact: Positive, as it addresses an immediate need for more efficient insulin delivery mechanisms. Long-term impact: Potentially transformative, as it may lead to widespread adoption and better quality of life for T2D patients, reducing the burden of diabetes management.
From a market perspective, embecta’s emphasis on a larger insulin reservoir in their patch pumps is a strategic move to meet a clear market demand. The study's findings indicate that a significant portion of T2D patients could benefit from fewer replacements, which translates into cost savings and convenience. This feature is likely to resonate well with both patients and healthcare providers.
The adoption of this technology could significantly affect embecta’s market position, particularly if the FDA grants approval for their 300u reservoir system. This innovation could potentially differentiate embecta in a competitive diabetes care market, leading to increased market share.
Short-term impact: Potential increase in stock value upon FDA approval and positive market reception. Long-term impact: Sustained growth opportunities as embecta captures a larger segment of the diabetes care market.
Financially, the introduction of a 300u insulin reservoir patch pump could be a significant revenue driver for embecta. The diabetes care market is continuously growing, driven by increasing prevalence and awareness. Embecta’s innovation positions it to capitalize on this growth by offering a product that meets a significant unmet need.
Looking at the numbers, reduced frequency of patch changes not only lowers costs for patients but potentially increases the margin on each patch due to higher perceived value and convenience. This could result in a higher average selling price per unit. Approval from the FDA would be a critical catalyst for stock price appreciation, as it would validate the product's safety and efficacy, opening doors for market penetration.
Short-term impact: Positive, contingent on FDA approval and market uptake. Long-term impact: Enhanced profit margins and sustained revenue growth as the product gains traction.
PARSIPPANY, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, presented two abstracts at the American Diabetes Association’s 84th Scientific Sessions that point to the potential for adults with type 2 diabetes (T2D) to better manage insulin delivery through a patch pump with a larger, 300-unit (u) insulin reservoir, which could provide longer wear times and fewer disposable patches over time.
In “Predictors of Insulin Total Daily Dose (TDD) in U.S. Adults with T2D on Multiple Daily Injections (MDI),” Viral N. Shah, M.D., Professor of Medicine, Division of Endocrinology & Metabolism and Director of Diabetes Clinical Research at the IU Center for Diabetes and Metabolic Diseases at Indiana University School of Medicine, and his co-authors analyzed 41,215 adults with T2D on multiple daily insulin injections who were prescribed a mean insulin TDD of 96 units of insulin to investigate demographic and clinical factors that could impact insulin dosage. The authors concluded that insulin TDD was greater by
In “Evaluating Need for Larger Insulin Reservoir in Patch Pumps: Leveraging Retrospective Dose Data for US Adults with T2D on MDI,” Eugene E. Wright Jr., M.D., Medical Director, South Piedmont Area Health Education Center, and co-authors analyzed adults with T2D on multiple daily injection therapy, estimating the number of people for whom 200u and 300u insulin reservoirs would be sufficient for different wear times and the number of patch pumps needed over time.
“Based on the mean total daily dose of 96±58 units of insulin per day in a cohort of 41,215 adults with T2D on MDI (> 3 injections per day), we noted that a 300u insulin reservoir would meet the needs of
"The data presented at the ADA Scientific Sessions this weekend reaffirms what we’ve learned from speaking with people living with diabetes and their healthcare providers: there is a critical unmet need among the T2D population for pumps with a larger insulin reservoir,” said Henry Anhalt, D.O., Chief Medical Officer, embecta. “As our mission is to make life better for people living with diabetes, we prioritized a 300u reservoir in the proprietary disposable insulin delivery system we submitted earlier this year to the U.S. Food and Drug Administration (FDA) in a 510(k) premarket filing.”
The ADA’s 84th Scientific Sessions are taking place June 21-24, 2024, in Orlando, Florida, and are accessible virtually.
About embecta
embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships, and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
Contacts:
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| Contact Media Relations | Contact IR |
FAQ
What did Embecta present at the ADA's 84th Scientific Sessions?
How does the 300u insulin reservoir benefit T2D patients?
What factors influence insulin total daily dose (TDD) in T2D patients?
What are the limitations of the 200u insulin reservoir for T2D patients?
Has Embecta submitted the 300u insulin delivery system for approval?
